



True precision medicine through single-cell science

- Best-in-class single-cell biomarker discovery algorithm
- Validated, patent-pending biomarkers for two indications
- First commercial deals signed and a global network of partners



Key achievement

Discovered a new biomarker for diagnosing endometriosis



- Scailyte has established its presence in the US:
 - Opened an office in Boston to strengthen US activities.
 - Engaged a top industry expert to lead business development in the US [Link](#).

- We doubled the number of datasets across projects →

- Our clinically relevant findings from the Covid19/ARDS project with CHU Rennes have been published in Cell Reports Medicine [Link](#).



- Prof Michael Brenner (Harvard Medical School) joined as scientific advisor to support the Board and management in defining our clinical and R&D strategy [Link](#)



Series A kicked off, first term sheet received

We are keen to explore the fit with investors from the life science space.

[Get in touch with us!](#)

Outlook for Q3-2021

- File new IP on our recent discoveries
- Close another commercial agreement





True precision medicine through single-cell science

- Best-in-class single-cell biomarker discovery algorithm
- Validated, patent-pending biomarkers for two indications
- First commercial deals signed and a global network of partners



Michael Brenner, MD

Professor at Harvard Medical School



QUOTE

“ With their approach to leverage single-cell data and artificial intelligence for biomarker discovery, Scailyte is spot on, doing something that has huge potential and at the right time. ”

Profile

Immunology Faculty Member at Brigham and Women’s Hospital of Harvard Medical School. His focus is on autoimmune diseases (rheumatoid arthritis) and immune cell activation. Prof Brenner supports multiple biotech and medical companies as an advisor.

QUOTE

“ I feel we are just beginning to scratch the surface of the medical innovation that is enabled by Scailyte’s single cell multi-omics. I believe that many lives can be saved with more reliable biomarkers either through earlier diagnosis or better match of patients to effective treatments. ”

Profile

Computational biologist with over a decade of technology development experience in the diagnostics and life sciences industries He plays a very active role in the innovation ecosystem in Boston, supporting startups as part of the board of directors as well as through mentoring. Executive advisor to Scailyte since May 2021, representing the company in the US.

Daniel Schoener

Executive Business Advisor



www.scailyte.com
[Dr. Peter Nestorov](#)
CEO & Co-founder